March 9, 2005Open Access

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Key Points

Key points are not available for this paper at this time.

Abstract

Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylated MGMT promoter did not have such a benefit.

MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

Key Points

Abstract

Cite This Study